Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
May 06 2021 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical
company developing multifunctional biotherapeutics, is pleased to
announce the detailed voting results on the items of business
considered at its Annual General Meeting of Shareholders held on
May 5, 2021 (the “Meeting”).
Shareholder Voting Results
The Shareholders voted on the following matters at this year’s
Meeting.
Proposal 1 – Election of Directors
The nominees listed in Zymeworks’ proxy statement dated March
23, 2021 (the “Proxy Statement”) were elected as Directors
of the Company. Detailed results of the votes are set out
below:
Proposal 1
Outcome of the Vote
Votes by Ballot
Election of Directors
Votes For
Votes Withheld
Susan Mahony
Carried
19,286,855 (71.48%)
7,695,418 (28.52%)
Kelvin Neu
Carried
19,377,998 (71.82%)
7,604,275 (28.18%)
Ali Tehrani
Carried
19,375,651 (71.81%)
7,606,622 (28.19%)
Proposal 2 – Advisory Vote on Executive Compensation
The Shareholders approved, on an advisory basis, the
compensation of the Company’s named executive officers. Detailed
results of the votes are set out below:
Proposal 2
Outcome of the Vote
Votes by Ballot
Votes For
Votes Against
Votes Abstaining
Advisory Vote on Executive
Compensation
Carried
24,095,093 (89.30%)
2,607,651 (9.66%)
279,529 (1.04%)
Proposal 3 – Appointment of Auditors
The vote was carried for the appointment of the Auditors, KPMG
LLP. Detailed results of the votes are set out below:
Proposal 3
Outcome of the Vote
Votes by Ballot
Votes For
Votes Withheld
Appointment of KPMG LLP
Carried
28,930,162 (98.99%)
296,499 (1.01%)
Full details of all proposals are fully described in the Proxy
Statement available on the Company’s profile on SEDAR at
www.sedar.com, and on EDGAR at www.sec.gov, and the detailed
results of voting on each proposal are included in the Report of
Voting Results filed on SEDAR and on EDGAR.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, zanidatamab (ZW25), is a novel Azymetric™
bispecific antibody which has been granted Breakthrough Therapy
designation by the FDA and is currently enrolling in a pivotal
clinical trial for refractory HER2-amplified biliary tract cancer
(HERIZON-BTC-01) as well as several Phase 2 clinical trials for
HER2-expressing gastroesophageal and breast cancers. Zymeworks’
second clinical candidate, ZW49, is a novel bispecific
HER2-targeting antibody-drug conjugate currently in Phase 1
clinical development and combines the unique design and antibody
framework of zanidatamab with Zymeworks’ proprietary ZymeLink™
linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For more information, visit
www.zymeworks.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210506005410/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com
Jack Spinks (604) 678-1388 ir@zymeworks.com
Media Inquiries: Mary Klem (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2023 to Sep 2024